2023, Number 1
<< Back Next >>
Med Int Mex 2023; 39 (1)
Liver failure as a complication of SARSCoV- 2 infection
Contreras-Pacheco AE, López-González JC, Montelongo-Santiesteban JJ, Valenzuela-Aldaba YE, Zermeño-Pacheco S, Sierra-Juárez MA, Pérez-Ruiz MD, Enríquez-Sánchez LB
Language: Spanish
References: 28
Page: 7-19
PDF size: 259.95 Kb.
ABSTRACT
Objective: To identify the different variables that can cause liver injury in a patient
hospitalized for COVID-19.
Materials and Methods: A prospective cohort study that included patients
with COVID-19 who were admitted to the Central University Hospital of the State of
Chihuahua from April 2020 to November 2020. A univariate analysis was performed
to find the frequencies of demographic characteristics and of the drugs prescribed, as
well as a comparison of means of the biochemical parameters using Student’s t test.
Results: One hundred thirty-four patients with a confirmed diagnosis of COVID-19
were included, who underwent liver function parameters and averages were obtained
on the day of admission, on the fifth day and the last values recorded for improvement
or death. Of the parameters, albumin levels showed a significant decrease on the 5th
and last day of hospitalization compared to the first day of admission. On the other
hand, the levels of alkaline phosphatase, gamma-glutamyl transferase and erythrocyte
sedimentation rate increased significantly on the 5th and last day of stay.
Conclusión: There are different mechanisms that can generate liver injury associated
with COVID-19. Of these, the uncontrolled inflammatory response that occurs
can alter liver function tests. Our results found a relationship between the alteration of
different laboratory parameters and the days of hospital stay of patients with the disease.
REFERENCES
Phelan AL, Katz R, Gostin LO. The novel coronavirus originatingin Wuhan, China: Challenges for Global HealthGovernance. JAMA 2020.
Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, Kim SH. Clinicalcharacteristics of asymptomatic and symptomatic patientswith mild COVID-19. Clinical microbiology and infection:the official publication of the European Society of ClinicalMicrobiology and Infectious Diseases 2020; 26 (7): 948.e1-948.e3. https://doi.org/10.1016/j.cmi.2020.04.040.
Guan W-J, Ni Z-Y, Hu Y, Liang W, et al. Clinical characteristicsof 2019 novel coronavirus infection in China. N Engl J Med2020. DOI:10.1056/NEJMoa2002032.
Russell B, Moss C, Rigg A, Hopkins C, Papa S, Van HemelrijckM. Anosmia and ageusia are emerging as symptoms inpatients with COVID-19: What does the current evidencesay? Ecancermedicalscience 2020; 14: ed98. doi:10.3332/ecancer.2020.ed98.
Alqahtani SA, Schattenberg JM. Liver injury in COVID-19:The current evidence. United European Gastroenterol J2020; 8 (5): 509-519. doi: 10.1177/2050640620924157.
Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highlypathogenic human coronavirus infections. Liver Int 2020;40 (5): 998-1004.
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologictreatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. https://doi.org/10.1001/jama.2020.6019.
Yang X, Yu Y, Xu J, Shu H, et al. Clinical course and outcomesof critically ill patients with SARS-CoV-2 pneumoniain Wuhan, China: a single-centered, retrospective, observationalstudy. Lancet Respir Med 2020. DOI:10.1016/S2213-2600(20)30079-5.
Huang C, Wang Y, Li X, Ren L, et al. Clinical features of patientsinfected with 2019 novel coronavirus in Wuhan, China.Lancet 2020; 395: 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.
Wu J, Song S, Cao HC, Li LJ. Liver diseases in COVID-19:Etiology, treatment and prognosis. World J Gastroenterol2020; 26 (19): 2286-22.
Bernal W, Wendon J. Acute liver failure. N Engl J Med 2013;369 (26): 2525-34. doi/10.1056/NEJMra1208937.
Rueda M, Lipsett PA. Hepatic failure. In: Martin ND, KaplanLJ, editors. Principles of Adult Surgical Critical Care [Internet].Cham: Springer International Publishing; 2016: 211-32.
Stravitz RT, Lee WM. Acute liver failure. Lancet 2019; 394(10201): 869-81. doi: 10.1016/S0140-6736(19)31894-X.
AlSamman M, Caggiula A, Ganguli S, Misak M, PourmandA. Non-respiratory presentations of COVID-19, a clinicalreview. Am J Emerg Med 2020; 38 (11): 2444-54. doi:10.1016/j.ajem.2020.09.054.
Kukla M, Skonieczna-Żydecka K, Kotfis K, Maciejewska D,Łoniewski I, Lara Luis F, et al. COVID-19, MERS and SARSwith concomitant liver injury—systematic review of theexisting literature. JCM 2020; 9 (5): 1420. doi: 10.3390/jcm9051420.
Chau T-N, Lee K-C, Yao H, Tsang T-Y, Chow T-C, Yeung Y-C,et al. SARS-associated viral hepatitis caused by a novelcoronavirus: Report of three cases. Hepatology 2004; 39(2): 302-10. doi: 10.1002/hep.20111.
Lagana SM, Kudose S, Iuga AC, Lee MJ, Fazlollahi L, RemottiHE, et al. Hepatic pathology in patients dying of COVID-19:a series of 40 cases including clinical, histologic, and virologicdata. Mod Pathol 2020; 33 (11): 2147-55. https://doi.org/10.1038/s41379-020-00649-x.
Allard L, Ouedraogo E, Molleville J, Bihan H, Giroux-LeprieurB, Sutton A, et al. Malnutrition: Percentage and associationwith prognosis in patients hospitalized for Coronavirusdisease 2019. Nutrients 2020; 12 (12): 3679. doi: 10.3390/nu12123679.
Eckart A, Struja T, Kutz A, Baumgartner A, Baumgartner T,Zurfluh S, et al. Relationship of nutritional status, inflammation,and serum albumin levels during acute illness: Aprospective study. Am J Med 2020; 133 (6): 713-722.e7.doi: 10.1016/j.amjmed.2019.10.031.
Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, RelaM. COVID-19 and the liver. J Hepatol 2020; 73 (5): 1231-40.doi: 10.1016/j.jhep.2020.06.006.
Violi F, Ceccarelli G, Cangemi R, Alessandri F, D’Ettorre G,Oliva A, et al. Hypoalbuminemia, coagulopathy, and vasculardisease in COVID-19. Circ Res 2020; 127 (3): 400-1.doi: 10.1161/CIRCRESAHA.120.317173.
Huang J, Cheng A, Kumar R, Fang Y, Chen G, Zhu Y, et al.Hypoalbuminemia predicts the outcome of COVID‐19independent of age and co‐morbidity. J Med Virol 2020;92 (10): 2152-8. doi: 10.1002/jmv.26003.
Arepally GM. Heparin-induced thrombocytopenia.Blood 2017; 129 (21): 2864-72. doi: 10.1182/blood-2016-11-709873.
Li J, Fan J-G. Characteristics and mechanism of liver injuryin 2019 coronavirus disease. J Clin Transl Hepatol 2020; 8:13-17. doi: 10.14218/JCTH.2020.00019.
Olry A, Meunier L, Délire B, Larrey D, et al. Drug-inducedliver injury and COVID-19 infection: The rules remainthe same. Drug Saf 2020; 43 (7): 615-617. doi: 10.1007/s40264-020-00954-z.
Hamming I, Timens W, Bulthuis M, Lely A, Navis G, vanGoor H. Tissue distribution of ACE2 protein, the functionalreceptor for SARS coronavirus. A first step in understandingSARS pathogenesis. J Pathol 2004; 203 (2): 631-7. http://doi.wiley.com/10.1002/path.1570.
Nardo A, Schneeweiss-Gleixner M, Bakail M, Dixon E, Lax S,Trauner M. Pathophysiological mechanisms of liver injuryin COVID-19. Liver Int 2020; 41 (1): 20-32. http://dx.doi.org/10.1111/liv.14730.
Bertolini A, Van de Peppel I, Bodewes F, Moshage H, FantinA, Farinati F, et al. Abnormal liver function tests in patientswith COVID-19: Relevance and potential pathogenesis. Hepatology2020; 72 (5): 1864-72. http://dx.doi.org/10.1002/hep.31480.